Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia
Autor: | Alfred Körfer, Johannes Meran, Mathias Freund, Simone Giller, Fokke Hinrichs, H. Link, Axel Baars, Hubert Poliwoda |
---|---|
Rok vydání: | 1991 |
Předmět: |
Adult
Amsacrine Male Cancer Research medicine.medical_specialty medicine.medical_treatment Gastroenterology Drug Administration Schedule Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Etoposide Aged Chemotherapy Hematology Dose-Response Relationship Drug business.industry Cytarabine Myeloid leukemia General Medicine Middle Aged medicine.disease Surgery Oncology Leukemia Myeloid Toxicity Acute Disease Female business medicine.drug |
Zdroj: | Journal of cancer research and clinical oncology. 117(5) |
ISSN: | 0171-5216 |
Popis: | Twenty-two patients with acute myeloid leukemia (AML), having a median age of 48.3 years (range 26–70; 10 male, 12 female), were treated with 4′-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA) 100 mg/m2 and cytosine arabinoside (AraC) 2×1000 mg/m2 i.v. on days 1–5. There were 2 M1, 8 M2, 9 M4, 2 M4 Eo, and 1 M5a. Of these, 12 achieved a complete remission, 3 a partial remission and 6 did not respond. The median remission duration was 9.0 months and the median overall survival 8.1 months. Side-effects of induction consisted mainly of haematological toxicity and infections with a median duration of WHO-grade-4 granulopenia and thrombopenia of 20 and 28 days respectively. Organ toxicity was mild with mucositis and cutaneous and liver toxicity being experienced by only a few patients. There was one treatment-related death. Five-day m-AMSA and intermediate-dose AraC is an easy-to-handle condensed treatment schedule with tolerable toxicity. Its effectiveness in relapsed and refractory AML is comparable to combinations of high-dose AraC with m-AMSA, anthracyclines or etoposide. |
Databáze: | OpenAIRE |
Externí odkaz: |